IXICO plc (LSE:IXI) has maintained its upgraded revenue guidance for 2026 and 2027 despite the cancellation of two Huntington’s disease clinical programmes that it was supporting.
The neuroscience imaging specialist said the impact on its order book has been offset by strong contract wins secured earlier in the year, allowing management to remain confident in the company’s financial outlook.
Order Book Remains Strong Following New Contract Wins
IXICO expects the discontinued Huntington’s disease studies to reduce its contracted order book by approximately £1.5 million over the next two financial years.
However, the company noted that it secured around £8.0 million of new Huntington’s disease-related contract awards during the first half of FY2026.
As a result, IXICO’s overall order book remains 21% higher than it was at the end of FY2025, providing continued revenue visibility and supporting the board’s decision to leave its upgraded guidance unchanged.
Management also continues to expect the business to meet or exceed current market forecasts.
AI Imaging Platform Supports Neurology Research
IXICO operates as an Imaging Contract Research Organisation, providing artificial intelligence-driven imaging analysis and biomarker services for neurological disease research.
Its proprietary IXI platform processes imaging data from clinical trials conducted around the world, helping researchers measure disease biomarkers and assess treatment effectiveness across conditions including Alzheimer’s disease, Huntington’s disease and Parkinson’s disease.
The company’s imaging specialists combine advanced analytics with clinical expertise to generate insights that support pharmaceutical companies and research organisations developing new neurological therapies.
Commercial Progress Offsets Financial Challenges
While IXICO continues to report operating losses and negative operating cash flow, management highlighted strong commercial momentum and improving operational leverage following recent contract wins.
The company also noted that a strengthened cash position following its recent capital raising provides additional financial flexibility.
Technical indicators remain supportive, although shares have moved into territory that some investors may view as overbought. Valuation also continues to be affected by the absence of profitability and a dividend.
About IXICO plc
IXICO plc is a specialist neuroscience imaging and biomarker analytics company that provides end-to-end imaging services for clinical trials in neurological diseases.
Using its AI-powered IXI platform, the company supports pharmaceutical companies, biotechnology firms, research consortia and non-profit organisations conducting studies in Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and other neurological conditions.
With more than two decades of experience, IXICO has analysed hundreds of thousands of medical images and developed a global network of specialist imaging centres, helping improve the consistency and reliability of clinical trial data.
Leave a Reply